ARD-61

Networked: 2 relevant articles (1 outcomes, 1 trials/studies)

1.	Han, Xin: 2 articles (10/2020 - 01/2020)
2.	Wang, Shaomeng: 2 articles (10/2020 - 01/2020)
3.	Lu, Jianfeng: 1 article (10/2020)
4.	McEachern, Donna: 1 article (10/2020)
5.	Zhao, Lijie: 1 article (10/2020)
6.	Apel, Ingrid J: 1 article (01/2020)
7.	Bawa, Pushpinder: 1 article (01/2020)
8.	Cao, Xuhong: 1 article (01/2020)
9.	Chinnaiyan, Arul M: 1 article (01/2020)
10.	Fernandez-Salas, Ester: 1 article (01/2020)

1.	Neoplasms (Cancer) 10/01/2020 - "ARD-61 effectively induces complete AR degradation in xenograft tumor tissue and is more effective than enzalutamide in achieving tumor growth inhibition in the MDA-MB-453 xenograft model in mice. " 10/01/2020 - "A highly potent PROTAC androgen receptor (AR) degrader ARD-61 effectively inhibits AR-positive breast cancer cell growth in vitro and tumor growth in vivo."
2.	Breast Neoplasms (Breast Cancer) 10/01/2020 - "In this study, we evaluated ARD-61 for its therapeutic potential and mechanism of action in breast cancer models in vitro and in vivo. " 10/01/2020 - "ARD-61 potently and effectively induces AR degradation in AR+ breast cancer cell lines and is much more potent than enzalutamide in inhibition of cell growth and induction of cell cycle arrest and/or apoptosis. " 10/01/2020 - "A highly potent PROTAC androgen receptor (AR) degrader ARD-61 effectively inhibits AR-positive breast cancer cell growth in vitro and tumor growth in vivo."
3.	Prostatic Neoplasms (Prostate Cancer) 01/01/2020 - "Compared to clinically-approved AR antagonists, administration of ARD-61 in vitro and in vivo results in more potent anti-proliferative, pro-apoptotic effects and attenuation of downstream AR target gene expression in prostate cancer cells. "

1.	enzalutamide
2.	Androgen Receptors (Androgen Receptor)
3.	snake venom protein C activator